Therakind

Executive Summary

Therakind is a UK-based biopharmaceutical company dedicated to developing and commercializing innovative small molecule medicines tailored for pediatric populations. Founded in 2013 and headquartered in London, the company addresses significant unmet medical needs by reformulating existing drugs into child-appropriate dosage forms, thereby improving treatment options and enabling clinical trials for children. With a focus on neurology and pediatrics, Therakind operates at the commercial stage, leveraging its expertise to bring safer, more effective therapies to young patients. Despite its small size (1-50 employees), the company has established a niche in pediatric drug development, a field often overlooked by larger pharmaceutical firms due to regulatory and commercial challenges. Therakind's business model centers on identifying approved drugs with potential for pediatric use and developing novel formulations that enhance safety, efficacy, and compliance. By doing so, the company not only expands therapeutic options for children but also extends the lifecycle of existing medicines. While specific financial details and product revenues are not publicly disclosed, Therakind's sustained operation since 2013 and its classification as a commercial-stage entity suggest a viable product portfolio. The company's focus on underserved pediatric indications positions it well for growth, particularly as regulatory incentives for pediatric drug development increase globally. However, limited public information on pipeline and financials constrains full assessment.

Upcoming Catalysts (preview)

• Q3 2026Approval of new pediatric formulation for a neurological condition60% success
• Q3 2026Partnership or licensing deal with a larger pharma for pediatric drug commercialization50% success
• Q3 2026Positive results from a clinical trial of a reformulated pediatric drug55% success